Scientific report:

March 26, 2020

https://www.nature.com/articles/s41598-020-60182-4#Fig1

A universal reporter cell line for bioactivity evaluation of engineered cytokine products

 

 

https://www.hindawi.com/journals/mi/2017/3578702/

Abstract

Glibenclamide is the most widely used sulfonylurea drug for the treatment of type 2 diabetes mellitus (DM). Recent studies have suggested that glibenclamide reduced adverse neuroinflammation and improved behavioral outcomes following central nervous system (CNS) injury. We reviewed glibenclamide’s anti-inflammatory effects: abundant evidences have shown that glibenclamide exerted an anti-inflammatory effect in respiratory, digestive, urological, cardiological, and CNS diseases, as well as in ischemia-reperfusion injury. Glibenclamide might block KATP channel, Sur1-Trpm4 channel, and NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome activation, decrease the production of proinflammatory mediators (TNF-α, IL-1β, and reactive oxygen species), and suppress the accumulation of inflammatory cells. Glibenclamide’s anti-inflammation warrants further investigation.

1. Introduction

Glibenclamide, an oral hypoglycemic agent, belongs to the class of sulfonylureas, and its clinical utilization dates back to the 1960s [1]. Actually, sulfonylureas were discovered accidentally, as the antimicrobial sulfonamides caused hypoglycemia in animals. Thereafter, glibenclamide has been used widely in the type II diabetes mellitus (DM).

https://www.researchgate.net/publication/281464479_Serotype_1_and_8_Pneumococci_Evade_Sensing_by_Inflammasomes_in_Human_Lung_Tissue

Leabright's Blog

Just another WordPress.com weblog

WordPress.com

WordPress.com is the best place for your personal blog or business site.